Developing precision medicine in a global world

Clinical Cancer Research

Volumn 20, Issue 6, 2014, Pages 1419-1427

  Rubin, Eric H ^a   Allen, Jeffrey D ^b   Nowak, Jan A ^c   Bates, Susan E ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Friends of Cancer Research   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER RESEARCH; COMPANION DIAGNOSTICS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST APPROVAL; GENETIC SCREENING; HUMAN; INTERMETHOD COMPARISON; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY CONTROL; REIMBURSEMENT; SEQUENCE ANALYSIS; GENETICS; MOLECULAR DIAGNOSIS; NEOPLASMS; PROCEDURES; TRENDS; UNITED STATES;

HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; UNITED STATES;

EID: 84896501123     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0091     Document Type: Article

References (32)

1. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008;21 Suppl 2:S8-S15.
2. Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Valenstein PN. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med 2010; 134:930-5.
3. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, et al. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw 2009;7 Suppl 6:S1-S21.
4. Raman G, Wallace B, Patel K, Lau J, Trikalinos TA. Update on Horizon Scans of Genetic Tests Currently Available for Clinical Use in Cancers. Technology Assessment Report. Tufts Evidence-based Practice Center 2011. Available from: www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/ id81TA.pdf.
5. Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients withcancer. ClinCancerRes2014;20: 1428-44.
6. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006;355:1054-5.
7. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementinggroup 1: gene expression and platinum resistance. Int J Mol Med 2004;14:959-70.
8. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair crosscomplementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-54.
9. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013;368:1101-10.
10. Besse B, Olaussen KA, Soria JC. ERCC1 and RRM1: ready for prime time? J Clin Oncol 2013;31:1050-60.
11. Hunter Z, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. The genomic landscape of Waldenstom's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2013 Dec 23. [Epub ahead of print].
12. Treon SP, Hunter ZR. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood 2013;121:4434-6.
13. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18-43.
14. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of American pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138: 241-56.
15. Raab SS, Grzybicki DM. Quality in cancer diagnosis. CA Cancer J Clin 2010;60:139-65.
16. Senderowicz AM, Pfaff O. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics. Clin Cancer Res 2014;20:1445-52.
17. Mansfield EA. FDAperspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 2014;20:1453-7.
18. Pignatti F, Ehmann F, Hemmings R, Jonsson B, Nuebling M, Papaluca-Amati M, et al. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European Union. Clin Cancer Res 2014;20:1458-68.
19. Byron SK, Crabb N, George E, Marlow M, Newland A. The health technology assessment of companion diagnostics: experience of NICE. Clin Cancer Res 2014;20:1469-76.
20. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-31.
21. Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med 2013;369:2369-71.
22. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013;12:358-69.
23. Peikoff K. I had my DNA picture taken, with varying results. New York Times 2013. Available from: www.nytimes.com/2013/12/31/science/i-had-my-dna- picture-taken-with-varying-results.html?-r=0.
24. Pennello GA. Analytical and clinical evaluation of biomarkers assays: when are biomarkers ready for prime time? Clin Trials 2013;10:666-76.
25. Landgren O, Staudt L. MYD88 L265P somatic mutation in IgM MGUS. N Engl J Med 2012;367:2255-6.
26. Ansell SM, Secreto FJ, Manske M, Braggio E, Hodge LS, Price-Troska T, et al.MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression. ASH Annual Meeting Abstracts 2012;120:2699.
27. Gachard N, Parrens M, Soubeyran I, Petit B, Marfak A, Rizzo D, et al. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas. Leukemia 2013;27: 183-9.
28. Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121:4504-11.
29. Jimenez C, Sebastian E, Chillon MC, Giraldo P, Mariano Hernandez J, Escalante F, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia 2013;27:1722-8.
30. Mori N, Ohwashi M, Yoshinaga K, Mitsuhashi K, Tanaka N, Teramura M, et al. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma. PLoS ONE 2013;8:e80088.
31. Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013;121:2522-8.
32. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013;121:2051-8.